共 50 条
Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk
被引:19
|作者:
Zhang, Hongtuan
[1
]
Wang, Andi
[1
,2
]
Ma, Hui
[3
]
Xu, Yong
[1
,2
]
机构:
[1] Tianjin Med Univ, Affiliated Hosp 2, Tianjin Key Lab Urol, Natl Key Clin Specialty Urol, Tianjin 300211, Peoples R China
[2] Tianjin Key Lab Urol, Tianjin, Peoples R China
[3] Tianjin Med Univ, Affiliated Hosp 2, Dept Obstet & Gynaecol, Tianjin 300211, Peoples R China
关键词:
Insulin receptor substrate 1;
Polymorphism;
Cancer;
Meta-analysis;
Association;
GROWTH-FACTOR-I;
COLORECTAL-CANCER;
BREAST-CANCER;
PROSTATE-CANCER;
GENETIC POLYMORPHISMS;
NO ASSOCIATION;
RECTAL-CANCER;
UNITED-STATES;
IRS1;
SUSCEPTIBILITY;
D O I:
10.1007/s13277-013-0855-3
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Epidemiological studies investigating the association between the insulin receptor substrate 1 (IRS1) gene Gly972Arg (rs1801278) polymorphism and various carcinomas risk reported conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. A comprehensive search was conducted to identify all eligible studies of IRS1 Gly972Arg polymorphism and cancer risk. Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the strength of the associations. A total of 16 independent studies, including 11,776 cases and 11,654 controls, were identified. When all studies were pooled, we found a significant association between IRS1 Gly972Arg polymorphism and increased cancer risk under dominant model (OR = 1.16, 95 %CI = 1.04-1.30, P = 0.007) and allelic model (OR = 1.16, 95 %CI = 1.02-1.30, P = 0.02). In subgroup analysis based on cancer type, increased cancer risk was found in ovarian cancer (dominant: OR = 1.55, 95 %CI = 1.17-2.05, P = 0.002; allelic: OR = 1.55, 95 %CI = 1.19-2.01, P = 0.001), breast cancer (allelic: OR = 1.12, 95 %CI = 1.00-1.26, P = 0.05), and other cancers (allelic: OR = 1.31, 95 %CI = 1.00-1.71, P = 0.05). When stratified by study types, significant associations were observed in both cohort studies (dominant: OR = 1.25, 95 %CI = 1.06-1.47, P = 0.007; allelic: OR = 1.25, 95 %CI = 1.07-1.46, P = 0.005) and case-control studies (dominant: OR = 1.15, 95 %CI = 1.01-1.31, P = 0.04). In the subgroup analyses by ethnicity, significantly increased cancer risk was suggested among both Caucasians (dominant: OR = 1.13, 95 %CI = 1.02-1.26, P = 0.02; allelic: OR = 1.13, 95 %CI = 1.03-1.25, P = 0.01) and mixed population (dominant: OR = 1.22, 95 %CI = 1.01-1.46, P = 0.04). Our investigations demonstrate that IRS1 Gly972Arg polymorphism was associated with an increased risk of cancer, and additional well-designed studies are warranted to validate these findings.
引用
收藏
页码:2929 / 2936
页数:8
相关论文